These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 16446752

  • 21. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
    Stonnington CM, Snyder PJ, Hentz JG, Reiman EM, Caselli RJ.
    J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
    [Abstract] [Full Text] [Related]

  • 22. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial.
    Kennelly S, Abdullah L, Kenny RA, Mathura V, Luis CA, Mouzon B, Crawford F, Mullan M, Lawlor B.
    Int J Geriatr Psychiatry; 2012 Apr; 27(4):415-22. PubMed ID: 21560164
    [Abstract] [Full Text] [Related]

  • 23. Apolipoprotein E genotype and gender influence response to tacrine therapy.
    Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S.
    Ann N Y Acad Sci; 1996 Dec 16; 802():101-10. PubMed ID: 8993489
    [Abstract] [Full Text] [Related]

  • 24. Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease.
    Blesa R, Aguilar M, Casanova JP, Boada M, Martínez S, Alom J, de la Hoz CH, Sancho J, Fernández O, Gil-Neciga E, Massó JF.
    Alzheimer Dis Assoc Disord; 2006 Dec 16; 20(4):248-54. PubMed ID: 17132969
    [Abstract] [Full Text] [Related]

  • 25. EEG functional connectivity and ApoE genotype in Alzheimer's disease and controls.
    Kramer G, van der Flier WM, de Langen C, Blankenstein MA, Scheltens P, Stam CJ.
    Clin Neurophysiol; 2008 Dec 16; 119(12):2727-32. PubMed ID: 18848805
    [Abstract] [Full Text] [Related]

  • 26. The CDC2 I-G-T haplotype associated with the APOE epsilon4 allele increases the risk of sporadic Alzheimer's disease in Sicily.
    Bosco P, Caraci F, Copani A, Spada RS, Sortino MA, Salluzzo R, Salemi M, Nicoletti F, Ferri R.
    Neurosci Lett; 2007 Jun 04; 419(3):195-8. PubMed ID: 17498878
    [Abstract] [Full Text] [Related]

  • 27. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug 01; 32(6):1538-44. PubMed ID: 18573585
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Reduced functional brain activity response in cognitively intact apolipoprotein E epsilon4 carriers.
    Lind J, Persson J, Ingvar M, Larsson A, Cruts M, Van Broeckhoven C, Adolfsson R, Bäckman L, Nilsson LG, Petersson KM, Nyberg L.
    Brain; 2006 May 01; 129(Pt 5):1240-8. PubMed ID: 16537568
    [Abstract] [Full Text] [Related]

  • 30. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults.
    Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, Hyde K, Chapman D, Craft S.
    Neurobiol Aging; 2004 Mar 01; 25(3):311-4. PubMed ID: 15123336
    [Abstract] [Full Text] [Related]

  • 31. Distribution of APOE genotypes in a memory clinic cohort.
    van der Flier WM, Pijnenburg YA, Schoonenboom SN, Dik MG, Blankenstein MA, Scheltens P.
    Dement Geriatr Cogn Disord; 2008 Mar 01; 25(5):433-8. PubMed ID: 18401171
    [Abstract] [Full Text] [Related]

  • 32. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D, Andersen HF.
    Dement Geriatr Cogn Disord; 2007 Mar 01; 24(2):138-45. PubMed ID: 17622761
    [Abstract] [Full Text] [Related]

  • 33. The association between delirium and the apolipoprotein E epsilon4 allele in the elderly.
    van Munster BC, Korevaar JC, de Rooij SE, Levi M, Zwinderman AH.
    Psychiatr Genet; 2007 Oct 01; 17(5):261-6. PubMed ID: 17728664
    [Abstract] [Full Text] [Related]

  • 34. Cerebral glucose metabolism in patients with AD and different APOE genotypes.
    Drzezga A, Riemenschneider M, Strassner B, Grimmer T, Peller M, Knoll A, Wagenpfeil S, Minoshima S, Schwaiger M, Kurz A.
    Neurology; 2005 Jan 11; 64(1):102-7. PubMed ID: 15642911
    [Abstract] [Full Text] [Related]

  • 35. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype.
    Reger MA, Watson GS, Frey WH, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S.
    Neurobiol Aging; 2006 Mar 11; 27(3):451-8. PubMed ID: 15964100
    [Abstract] [Full Text] [Related]

  • 36. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R.
    Methods Find Exp Clin Pharmacol; 2007 Jul 11; 29 Suppl A():1-91. PubMed ID: 17957277
    [Abstract] [Full Text] [Related]

  • 37. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.
    Darreh-Shori T, Brimijoin S, Kadir A, Almkvist O, Nordberg A.
    Neurobiol Dis; 2006 Nov 11; 24(2):326-33. PubMed ID: 16973370
    [Abstract] [Full Text] [Related]

  • 38. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.
    Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, Woodruff BK, Alexander GE, Osborne D.
    Arch Neurol; 2007 Sep 11; 64(9):1306-11. PubMed ID: 17846270
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.